1056 related articles for article (PubMed ID: 22323736)
1. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.
Cramer PE; Cirrito JR; Wesson DW; Lee CY; Karlo JC; Zinn AE; Casali BT; Restivo JL; Goebel WD; James MJ; Brunden KR; Wilson DA; Landreth GE
Science; 2012 Mar; 335(6075):1503-6. PubMed ID: 22323736
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease.
Mandrekar-Colucci S; Karlo JC; Landreth GE
J Neurosci; 2012 Jul; 32(30):10117-28. PubMed ID: 22836247
[TBL] [Abstract][Full Text] [Related]
3. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
Veeraraghavalu K; Zhang C; Miller S; Hefendehl JK; Rajapaksha TW; Ulrich J; Jucker M; Holtzman DM; Tanzi RE; Vassar R; Sisodia SS
Science; 2013 May; 340(6135):924-f. PubMed ID: 23704555
[TBL] [Abstract][Full Text] [Related]
4. Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway.
Zhao J; Fu Y; Liu CC; Shinohara M; Nielsen HM; Dong Q; Kanekiyo T; Bu G
J Biol Chem; 2014 Apr; 289(16):11282-11292. PubMed ID: 24599963
[TBL] [Abstract][Full Text] [Related]
5. The Continuing Failure of Bexarotene in Alzheimer's Disease Mice.
Balducci C; Paladini A; Micotti E; Tolomeo D; La Vitola P; Grigoli E; Richardson JC; Forloni G
J Alzheimers Dis; 2015; 46(2):471-82. PubMed ID: 25777514
[TBL] [Abstract][Full Text] [Related]
6. ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice.
Corona AW; Kodoma N; Casali BT; Landreth GE
J Neuroimmune Pharmacol; 2016 Mar; 11(1):61-72. PubMed ID: 26175148
[TBL] [Abstract][Full Text] [Related]
7. Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.
Tai LM; Koster KP; Luo J; Lee SH; Wang YT; Collins NC; Ben Aissa M; Thatcher GRJ; LaDu MJ
J Biol Chem; 2014 Oct; 289(44):30538-30555. PubMed ID: 25217640
[TBL] [Abstract][Full Text] [Related]
8. Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice.
Skerrett R; Pellegrino MP; Casali BT; Taraboanta L; Landreth GE
J Biol Chem; 2015 Aug; 290(35):21591-602. PubMed ID: 26163517
[TBL] [Abstract][Full Text] [Related]
9. Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.
Bonet-Costa V; Herranz-Pérez V; Blanco-Gandía M; Mas-Bargues C; Inglés M; Garcia-Tarraga P; Rodriguez-Arias M; Miñarro J; Borras C; Garcia-Verdugo JM; Viña J
J Alzheimers Dis; 2016; 51(3):701-11. PubMed ID: 26890773
[TBL] [Abstract][Full Text] [Related]
10. Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
Landreth GE; Cramer PE; Lakner MM; Cirrito JR; Wesson DW; Brunden KR; Wilson DA
Science; 2013 May; 340(6135):924-g. PubMed ID: 23704556
[TBL] [Abstract][Full Text] [Related]
11. Cooperative therapeutic action of retinoic acid receptor and retinoid x receptor agonists in a mouse model of Alzheimer's disease.
Kawahara K; Suenobu M; Ohtsuka H; Kuniyasu A; Sugimoto Y; Nakagomi M; Fukasawa H; Shudo K; Nakayama H
J Alzheimers Dis; 2014; 42(2):587-605. PubMed ID: 24916544
[TBL] [Abstract][Full Text] [Related]
12. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
Fitz NF; Cronican AA; Lefterov I; Koldamova R
Science; 2013 May; 340(6135):924-c. PubMed ID: 23704552
[TBL] [Abstract][Full Text] [Related]
13. RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment.
Lefterov I; Schug J; Mounier A; Nam KN; Fitz NF; Koldamova R
Neurobiol Dis; 2015 Oct; 82():132-140. PubMed ID: 26071899
[TBL] [Abstract][Full Text] [Related]
14. Critical role of astroglial apolipoprotein E and liver X receptor-α expression for microglial Aβ phagocytosis.
Terwel D; Steffensen KR; Verghese PB; Kummer MP; Gustafsson JÅ; Holtzman DM; Heneka MT
J Neurosci; 2011 May; 31(19):7049-59. PubMed ID: 21562267
[TBL] [Abstract][Full Text] [Related]
15. Stimulation of the retinoid X receptor facilitates beta-amyloid clearance across the blood-brain barrier.
Bachmeier C; Beaulieu-Abdelahad D; Crawford F; Mullan M; Paris D
J Mol Neurosci; 2013 Feb; 49(2):270-6. PubMed ID: 22890420
[TBL] [Abstract][Full Text] [Related]
16. New hope from an old drug: fighting Alzheimer's disease with the cancer drug bexarotene (targretin)?
Aicardi G
Rejuvenation Res; 2013 Dec; 16(6):524-8. PubMed ID: 24047423
[TBL] [Abstract][Full Text] [Related]
17. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
Tesseur I; Lo AC; Roberfroid A; Dietvorst S; Van Broeck B; Borgers M; Gijsen H; Moechars D; Mercken M; Kemp J; D'Hooge R; De Strooper B
Science; 2013 May; 340(6135):924-e. PubMed ID: 23704554
[TBL] [Abstract][Full Text] [Related]
18. ApoE promotes the proteolytic degradation of Abeta.
Jiang Q; Lee CY; Mandrekar S; Wilkinson B; Cramer P; Zelcer N; Mann K; Lamb B; Willson TM; Collins JL; Richardson JC; Smith JD; Comery TA; Riddell D; Holtzman DM; Tontonoz P; Landreth GE
Neuron; 2008 Jun; 58(5):681-93. PubMed ID: 18549781
[TBL] [Abstract][Full Text] [Related]
19. Nuclear receptor agonist-driven modification of inflammation and amyloid pathology enhances and sustains cognitive improvements in a mouse model of Alzheimer's disease.
Casali BT; Reed-Geaghan EG; Landreth GE
J Neuroinflammation; 2018 Feb; 15(1):43. PubMed ID: 29448961
[TBL] [Abstract][Full Text] [Related]
20. Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene.
Boehm-Cagan A; Michaelson DM
J Neurosci; 2014 May; 34(21):7293-301. PubMed ID: 24849361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
